Learn more →
Back to Expert Scholars
clinical / clinicalPediatric Oncology

Eric Bouffet

埃里克·布费

MD, FRCP(C)

🏢The Hospital for Sick Children (SickKids), University of Toronto(多伦多病童医院/多伦多大学)🌐Canada

Division Head, Haematology/Oncology; Garron Family Chair in Childhood Cancer Research血液肿瘤科主任;儿童癌症研究Garron家族讲席教授

59
h-index
3
Key Papers
5
Awards
3
Key Contributions

👥Biography 个人简介

Eric Bouffet is a globally renowned pediatric neuro-oncologist at SickKids Toronto who has led pivotal DIPG and pediatric CNS tumor trials for decades, championed BRAF-targeted therapy for pediatric gliomas, and established international collaborative frameworks advancing treatment for children with brain tumors.

Share:

🧪Research Fields 研究领域

DIPG弥漫性内生性桥脑胶质瘤
Pediatric CNS Tumors儿童中枢神经系统肿瘤
BRAF-Targeted TherapyBRAF靶向治疗
Pediatric Neuro-Oncology Clinical Trials儿童神经肿瘤临床试验

🎓Key Contributions 主要贡献

DIPG Clinical Trials Leadership

Led and co-led multiple international phase I/II trials in DIPG including ONC201, convection-enhanced delivery, and combination immunotherapy approaches, advancing the clinical evidence base.

BRAF-Targeted Therapy in Pediatric Glioma

Pioneered use of vemurafenib and dabrafenib/trametinib in BRAF V600E-mutant pediatric gliomas through early-phase trials, establishing targeted therapy as standard of care.

International Pediatric Neuro-Oncology Collaboration

Co-founded and led SIOPE's Brain Tumour Group and Pacific Pediatric Neuro-Oncology Consortium (PNOC), enabling multi-continental trials in rare pediatric brain tumors.

Representative Works 代表性著作

[1]

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas

European Journal of Cancer (2018)

Demonstrated clinical activity of BRAF inhibition in pediatric high-grade glioma, supporting targeted therapy approaches.

[2]

Immunotherapy in pediatric brain tumors: past, present, and future

Neuro-Oncology (2021)

Comprehensive review of immunotherapy landscape in pediatric CNS tumors, outlining rational combination strategies.

[3]

ONC201 for H3K27M-mutant pediatric diffuse midline glioma after radiotherapy

Nature Medicine (2023)

Multi-center study demonstrating ONC201 efficacy and tolerability in H3K27M-mutant DMG patients post-irradiation.

🏆Awards & Recognition 奖项与荣誉

🏆SIOPE Award for Outstanding Contribution to Pediatric Oncology in Europe
🏆ASPHO Distinguished Career Award
🏆University of Toronto Faculty of Medicine Award of Excellence
🏆Canadian Cancer Society Research Scientist Award
🏆ISPNO Lifetime Achievement Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 埃里克·布费 的研究动态

Follow Eric Bouffet's research updates

留下邮箱,当我们发布与 Eric Bouffet(The Hospital for Sick Children (SickKids), University of Toronto)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment